» Articles » PMID: 39054334

Modelling Onchocerciasis-associated Epilepsy and the Impact of Ivermectin Treatment on Its Prevalence and Incidence

Overview
Journal Nat Commun
Specialty Biology
Date 2024 Jul 25
PMID 39054334
Authors
Affiliations
Soon will be listed here.
Abstract

Retrospective cohort studies in Cameroon found an association between Onchocerca volvulus microfilarial load in childhood (measured in 1991-1993) and risk of developing epilepsy later in life (measured in 2017). We parameterised and integrated this relationship (across children aged 3-15 years) into the previously published, stochastic transmission model, EPIONCHO-IBM, for Simulium damnosum sensu lato-transmitted onchocerciasis. We simulated 19 years (1998-2017) of annual ivermectin mass drug administration (MDA) reflecting coverage in the study area, and modelled epilepsy prevalence and incidence. Scenario-based simulations of 25 years of (annual and biannual) MDA in hyper- and holoendemic settings, with 65% and 80% therapeutic coverage, were also conducted. EPIONCHO-IBM predicted 7.6% epilepsy prevalence (compared to 8.2% in the Cameroon study) and incidence of 317 cases/100,000 person-years (compared to 350). In hyperendemic areas, 25 years of biannual MDA (80% coverage) eliminated onchocerciasis-associated epilepsy (OAE) and protected untreated under-fives from its development. Strengthening onchocerciasis programmes, implementing alternative strategies, and evaluating treatment for under-fives and school-age children are crucial to prevent OAE in highly-endemic settings.

Citing Articles

Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy.

Manavi M, Mohammad Jafari R, Shafaroodi H, Sharifzadeh M, Dehpour A Epilepsia Open. 2024; 10(1):361-367.

PMID: 39585722 PMC: 11803276. DOI: 10.1002/epi4.13107.


Crystal structure of N-terminally hexahistidine-tagged Onchocerca volvulus macrophage migration inhibitory factor-1.

Kimble A, Dawson O, Liu L, Subramanian S, Cooper A, Battaile K Acta Crystallogr F Struct Biol Commun. 2024; .

PMID: 39503735 PMC: 11614107. DOI: 10.1107/S2053230X24010550.

References
1.
Kamga G, Dissak-Delon F, Nana-Djeunga H, Biholong B, Mbigha-Ghogomu S, Souopgui J . Still mesoendemic onchocerciasis in two Cameroonian community-directed treatment with ivermectin projects despite more than 15 years of mass treatment. Parasit Vectors. 2016; 9(1):581. PMC: 5109673. DOI: 10.1186/s13071-016-1868-8. View

2.
Boussinesq M, Pion S, Demanga-Ngangue , Kamgno J . Relationship between onchocerciasis and epilepsy: a matched case-control study in the Mbam Valley, Republic of Cameroon. Trans R Soc Trop Med Hyg. 2002; 96(5):537-41. DOI: 10.1016/s0035-9203(02)90433-5. View

3.
Kura K, Milton P, Hamley J, Walker M, Bakajika D, Kanza E . Can mass drug administration of moxidectin accelerate onchocerciasis elimination in Africa?. Philos Trans R Soc Lond B Biol Sci. 2023; 378(1887):20220277. PMC: 10440165. DOI: 10.1098/rstb.2022.0277. View

4.
Hamley J, Milton P, Walker M, Basanez M . Modelling exposure heterogeneity and density dependence in onchocerciasis using a novel individual-based transmission model, EPIONCHO-IBM: Implications for elimination and data needs. PLoS Negl Trop Dis. 2019; 13(12):e0007557. PMC: 7006940. DOI: 10.1371/journal.pntd.0007557. View

5.
Chesnais C, Bizet C, Campillo J, Njamnshi W, Bopda J, Nwane P . A Second Population-Based Cohort Study in Cameroon Confirms the Temporal Relationship Between Onchocerciasis and Epilepsy. Open Forum Infect Dis. 2020; 7(6):ofaa206. PMC: 7304933. DOI: 10.1093/ofid/ofaa206. View